BLUE vs. SGMO, DBVT, BCAB, LIFE, MOLN, OMGA, SCLX, OTLK, VIGL, and CRIS
Should you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include Sangamo Therapeutics (SGMO), DBV Technologies (DBVT), BioAtla (BCAB), aTyr Pharma (LIFE), Molecular Partners (MOLN), Omega Therapeutics (OMGA), Scilex (SCLX), Outlook Therapeutics (OTLK), Vigil Neuroscience (VIGL), and Curis (CRIS). These companies are all part of the "biological products, except diagnostic" industry.
Sangamo Therapeutics (NASDAQ:SGMO) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
Sangamo Therapeutics has higher revenue and earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 2.8% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 2.1% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Sangamo Therapeutics currently has a consensus target price of $5.67, suggesting a potential upside of 772.33%. bluebird bio has a consensus target price of $5.74, suggesting a potential upside of 457.71%. Given bluebird bio's stronger consensus rating and higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than bluebird bio.
bluebird bio has a net margin of -419.64% compared to bluebird bio's net margin of -1,749.06%. Sangamo Therapeutics' return on equity of -34.32% beat bluebird bio's return on equity.
In the previous week, Sangamo Therapeutics had 5 more articles in the media than bluebird bio. MarketBeat recorded 15 mentions for Sangamo Therapeutics and 10 mentions for bluebird bio. bluebird bio's average media sentiment score of 0.48 beat Sangamo Therapeutics' score of 0.02 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
bluebird bio received 596 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.
Summary
Sangamo Therapeutics and bluebird bio tied by winning 9 of the 18 factors compared between the two stocks.
Get bluebird bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
bluebird bio Competitors List
Related Companies and Tools
